ZyVersa Operating Income vs Selling And Marketing Expenses Analysis
| ZVSA Stock | 1.14 0.01 0.87% |
ZyVersa Therapeutics financial indicator trend analysis is more than just analyzing ZyVersa Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ZyVersa Therapeutics is a good investment. Please check the relationship between ZyVersa Therapeutics Operating Income and its Selling And Marketing Expenses accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.
Operating Income vs Selling And Marketing Expenses
Operating Income vs Selling And Marketing Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ZyVersa Therapeutics Operating Income account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have strong relationship.
The correlation between ZyVersa Therapeutics' Operating Income and Selling And Marketing Expenses is 0.69. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of ZyVersa Therapeutics, assuming nothing else is changed. The correlation between historical values of ZyVersa Therapeutics' Operating Income and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of ZyVersa Therapeutics are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Operating Income i.e., ZyVersa Therapeutics' Operating Income and Selling And Marketing Expenses go up and down completely randomly.
Correlation Coefficient | 0.69 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Operating Income
Operating Income is the amount of profit realized from ZyVersa Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ZyVersa Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Selling And Marketing Expenses
Most indicators from ZyVersa Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ZyVersa Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.At present, ZyVersa Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 14.3 M, whereas Tax Provision is projected to grow to (8.4 M).
| 2023 | 2024 (projected) | Interest Expense | 457K | 444.5K | Depreciation And Amortization | 9.4K | 8.3K |
ZyVersa Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
ZyVersa Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.